American Association for Cancer Research
10780432ccr183789-sup-212468_2_supp_5366386_pnhzn6.xlsx (50.4 kB)

Supplementary Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

Download (50.4 kB)
posted on 2023-03-31, 20:46 authored by Elizabeth Won, Azfar Basunia, Walid K. Chatila, Jaclyn F. Hechtman, Joanne F. Chou, Geoffrey Y. Ku, Sree B. Chalasani, Michelle S. Boyar, Zoe Goldberg, Avni M. Desai, Yaelle Tuvy, Michael F. Berger, Laura Tang, David P. Kelsen, Mark Schattner, David H. Ilson, Marinela Capanu, David B. Solit, Nikolaus Schultz, Yelena Y. Janjigian

Supplementary Table 3


NCI Cancer Center Core grant



VEGFR2-directed therapy is commonly used to treat metastatic esophagogastric cancer, but disease progresses in most patients within months. Therapeutic resistance is likely mediated in part by co-occurring amplifications of the genes for multiple oncogenic receptor tyrosine kinases (RTK). We therefore tested the efficacy of combined inhibition of VEGFR1-3, PDGFα/β, and FGFR1-3 using nintedanib. Patients with metastatic esophagogastric adenocarcinoma and disease progression on first-line chemotherapy were treated with nintedanib 200 mg twice daily. The primary endpoint was progression-free survival (PFS) at 6 months; secondary endpoints included tumor response and safety. Tumor biopsies were profiled by targeted capture next-generation sequencing (NGS) to identify molecular predictors of drug response. The study achieved its primary endpoint; 6 of 32 patients (19%) were progression-free at 6 months. With a median follow-up of 14.5 months among survivors, median overall survival (OS) was 14.2 months [95% confidence interval (CI), 10.8 months–NR]. Nintedanib was well tolerated; grade ≥ 3 toxicities were uncommon and included grade 3 hypertension (15%) and liver enzyme elevation (4%). FGFR2 alterations were identified in 18% of patients but were not predictive of clinical outcome on nintedanib therapy. Alterations in cell-cycle pathway genes were associated with worse median PFS (1.61 months for patients with cell-cycle pathway alterations vs. 2.66 months for patients without, P = 0.019). Nintedanib treatment resulted in modest disease stabilization in patients with metastatic esophagogastric cancer. Alterations in cell-cycle pathway genes and increased global copy-number alteration (CNA) burden warrant further study as prognostic or predictive biomarkers.

Usage metrics

    Clinical Cancer Research



    Ref. manager